ArticlePloS one2025
IGF-1 downregulates matrix metalloproteinase 8 to promote plaque stability: Evidence from myeloid cell-specific MMP8 in atherosclerosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of Matrix Metalloproteinase-8 Gene Polymorphisms and Their Association with Long-Term Survival, Clinical Phenotype, and Disease Risk in Patients with Coronary Artery Disease.International journal of molecular sciences · 2026Article
- Progress in research on the association between glucose metabolism disorders and intracranial and extracranial atherosclerotic stenosis.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND &
aimsMacrophages (MF) play an important role in atherosclerosis, a chronic inflammatory disease. Matrix metalloproteinase 8 (MMP8), a collagen degrading enzyme, is expressed by inflammatory cells. Systemic MMP8 deficiency reduces plaque MF and increases collagen suggesting increased plaque stability, however contribution of MF specific MMP8 is unknown. We previously found in Apolipoprotein E-/- mice, Insulin-Like Growth Factor-1 (IGF-1) overexpression in MF reduced MMP8, decreased atherosclerotic plaque MF, and upregulated features of stable atherosclerotic plaque. Thus, we hypothesized that MF specific MMP8 deficiency would reduce plaque burden and promote stability.
methodsWe used human THP-1 and murine MMP8 deficient MF for in vitro investigation of IGF-1 effect. We generated mice with MF MMP8-deficiency (mM8-:M8 + mice) or MF MMP8-rescue (mM8+ :M8-) by bone marrow transplantation after irradiation; IGF-1 was administered to these and control mice.
resultsWe found IGF-1 reduced MMP8 and suppressed collagenase activity in cultured MF. In Apolipoprotein E-/- mice, MF specific IGF-1 overexpression decreased plaque MMP8 levels and pro-inflammatory cytokines. MMP8 deficient MF had decreased levels of M1 markers and increased expression of M2 markers. We found no difference in atherosclerotic burden between groups, moreover, the ability of IGF-1 to increase collagen production depends on the ability of macrophages to express MMP8. This in vivo effect was only found in females.
conclusionsIGF-1 downregulated plaque MMP8 levels in control mice, however this effect was markedly blunted in mM8-:M8 + mice showing that macrophages are the main target of IGF-1 downregulation of plaque MMP8. Overall, our results suggest that macrophage MMP8 may be a potential target to treat unstable atherosclerotic plaques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.